Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review
Anna Gonzalez,1 Quinn Kistenfeger,2 Casey M Cosgrove1 1Division of Gynecologic Oncology; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 2Division of Obstetrics & Gynecology; The Ohio State University, Columbus, OH,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | International Journal of Women's Health |
| Subjects: | |
| Online Access: | https://www.dovepress.com/patient-selection-for-the-use-of-niraparib-in-advanced-ovarian-cancer--peer-reviewed-fulltext-article-IJWH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244482167996416 |
|---|---|
| author | Gonzalez A Kistenfeger Q Cosgrove CM |
| author_facet | Gonzalez A Kistenfeger Q Cosgrove CM |
| author_sort | Gonzalez A |
| collection | DOAJ |
| description | Anna Gonzalez,1 Quinn Kistenfeger,2 Casey M Cosgrove1 1Division of Gynecologic Oncology; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 2Division of Obstetrics & Gynecology; The Ohio State University, Columbus, OH, USACorrespondence: Anna Gonzalez, Email anna.gonzalez@osumc.eduAbstract: The advent of poly(ADP-ribose) polymerase (PARP) inhibitors has resulted in a significant paradigm shift in ovarian cancer treatment. Niraparib, a potent PARP inhibitor, has demonstrated substantial efficacy in both first-line and recurrent disease settings. By targeting homologous recombination DNA repair, a pathway frequently disrupted in ovarian cancer, particularly in the context of BRCA mutations, niraparib induces synthetic lethality. Pivotal clinical trials, including PRIMA, ENGOT-OV16/NOVA, and QUADRA, have solidified niraparib’s role in the treatment paradigm. While sharing a common mechanism of action with other PARP inhibitors, niraparib exhibits a distinct toxicity profile. Notably, hematologic toxicities, particularly thrombocytopenia, and hypertension have been observed at Grade 3– 4 levels. A comprehensive understanding of niraparib’s efficacy and safety is essential for optimal patient selection and management.Keywords: Niraparib, ovarian cancer, maintenance therapy, recurrent |
| format | Article |
| id | doaj-art-83a141ef56064bf2b19188475ebf330e |
| institution | OA Journals |
| issn | 1179-1411 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Women's Health |
| spelling | doaj-art-83a141ef56064bf2b19188475ebf330e2025-08-20T01:59:43ZengDove Medical PressInternational Journal of Women's Health1179-14112024-12-01Volume 162239224698575Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A ReviewGonzalez AKistenfeger QCosgrove CMAnna Gonzalez,1 Quinn Kistenfeger,2 Casey M Cosgrove1 1Division of Gynecologic Oncology; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, OH, USA; 2Division of Obstetrics & Gynecology; The Ohio State University, Columbus, OH, USACorrespondence: Anna Gonzalez, Email anna.gonzalez@osumc.eduAbstract: The advent of poly(ADP-ribose) polymerase (PARP) inhibitors has resulted in a significant paradigm shift in ovarian cancer treatment. Niraparib, a potent PARP inhibitor, has demonstrated substantial efficacy in both first-line and recurrent disease settings. By targeting homologous recombination DNA repair, a pathway frequently disrupted in ovarian cancer, particularly in the context of BRCA mutations, niraparib induces synthetic lethality. Pivotal clinical trials, including PRIMA, ENGOT-OV16/NOVA, and QUADRA, have solidified niraparib’s role in the treatment paradigm. While sharing a common mechanism of action with other PARP inhibitors, niraparib exhibits a distinct toxicity profile. Notably, hematologic toxicities, particularly thrombocytopenia, and hypertension have been observed at Grade 3– 4 levels. A comprehensive understanding of niraparib’s efficacy and safety is essential for optimal patient selection and management.Keywords: Niraparib, ovarian cancer, maintenance therapy, recurrenthttps://www.dovepress.com/patient-selection-for-the-use-of-niraparib-in-advanced-ovarian-cancer--peer-reviewed-fulltext-article-IJWHniraparibovarian cancermaintenance therapyrecurrent |
| spellingShingle | Gonzalez A Kistenfeger Q Cosgrove CM Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review International Journal of Women's Health niraparib ovarian cancer maintenance therapy recurrent |
| title | Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review |
| title_full | Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review |
| title_fullStr | Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review |
| title_full_unstemmed | Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review |
| title_short | Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review |
| title_sort | patient selection for the use of niraparib in advanced ovarian cancer a review |
| topic | niraparib ovarian cancer maintenance therapy recurrent |
| url | https://www.dovepress.com/patient-selection-for-the-use-of-niraparib-in-advanced-ovarian-cancer--peer-reviewed-fulltext-article-IJWH |
| work_keys_str_mv | AT gonzaleza patientselectionfortheuseofniraparibinadvancedovariancancerareview AT kistenfegerq patientselectionfortheuseofniraparibinadvancedovariancancerareview AT cosgrovecm patientselectionfortheuseofniraparibinadvancedovariancancerareview |